Medicare locks in permanent dialysis drug subsidies, bypassing cost controls

What it does

This bill extends and expands Medicare payment protections for new kidney dialysis drugs, devices, and education services. It guarantees that new dialysis medications approved since 2020 receive enhanced reimbursement for at least 3 years, then a permanent 65% add-on payment thereafter; extends similar protections to new dialysis equipment; requires Medicare Advantage plans to match these payments; and adds kidney disease screening and education to Medicare benefits. The primary beneficiaries are dialysis drug and device manufacturers, dialysis facilities, and patients with end-stage renal disease who gain access to newer treatments.

Why we flagged it

The bill's core mechanism is a multi-year reimbursement guarantee for new dialysis drugs and devices, structured to ensure manufacturers receive above-cost payments. While framed as expanding patient access, the primary fiscal effect is a guaranteed revenue stream for the dialysis sector.

What the text implies

• The 'permanent post-TDAPA adjustment' (Section 1) creates an indefinite entitlement to 65% of drug costs, with no sunset or budget-neutrality requirement—this is a permanent fiscal commitment that grows with new drug approvals and inflation.
• The bill explicitly exempts the adjustment from 'budget neutral manner' and 'patient-level case-mix adjustments,' meaning it bypasses standard Medicare cost-control mechanisms and will increase overall dialysis spending without offsetting reductions elsewhere.

The full analysis lists 5 implications of this text.

Who stands to gain

dialysis drug manufacturers; dialysis device manufacturers; renal dialysis facilities and chains